Ulta Beauty sees FY2 EPS $18.20-$18.70, consensus $17.84 16:12 ULTA Sees FY22 revenue $9.05B-$9.15B, consensus $9.14B. Sees FY22 SSS up 3%-4%.
Van-- looks ok but I think we can get a more powerful stock in here what do you think?
It's so expensive anyway maybe take a look at one of these two-- They are both pre approved by GBA-
1-Clearside Biomedical reports Q4 EPS 31c, consensus 16c 16:40 CLSD Reports Q4 revenue $25.69M, consensus $17.77M. "Our suprachoroidal injection platform is a proven approach for ocular drug delivery that offers potential advantages over other types of administration," said George Lasezkay, Clearside's president and CEO. "Following the approval and launch of XIPERE(TM), the first product approved for suprachoroidal delivery, there is a growing base of retinal specialists trained to use our proprietary SCS Microinjector(R). With more than 1,200 clinical injections to date and six clinical trials underway using our technology, we have established our leadership in this space."
2-Beauty Health initiated with an Overweight at JPMorgan 04:46 SKIN JPMorgan analyst Allen Gong initiated coverage of Beauty Health with an Overweight rating and $24 price target. The company's signature HydraFacial technology serves as a "differentiated platform that bridges the gap" between professional medical treatments and "more approachable" consumer skincare, Gong tells investors in a research note. The analyst says this gives Beauty Health exposure to $200B-plus of global markets with a focus on higher-growth sub-segments like domestic med spa and specialist skin-care growing in the double digits.
Chewy initiated with a Buy at Deutsche Bank 17:22 CHWY Deutsche Bank analyst Lee Horowitz initiated coverage of Chewy with a Buy rating and $55 price target. Despite near-term cost pressures, the analyst believes the market is "under appreciating the sustainability of Chewy's long-term growth profile from a total user, per user spend, and gross profit perspectives," and sees the stock as a "compelling" growth investment at current levels.